Ro CEO on the next phase of the Ozempic boom
Zach Reitano discusses scaling GLP-1 care, tackling backlash, and what comes after weight-loss drugs go mainstream.
Since first appearing on the Masters of Scale podcast at the height of the Ozempic-Wegovy-Zepbound boom, Zach Reitano, CEO of Ro, has helped scale his company into a leading provider of branded GLP-1s—grabbing headlines with a 2026 Super Bowl ad featuring tennis champion Serena Williams and landing a major partnership with Novo Nordisk for the pill version of Wegovy. Now Reitano has new challenges to address: the long-term health unknowns of the medications, the cultural backlash to “Ozempic face,” and what this wave of disruption could mean not just for pharma but for the future of healthcare.
What did you think of this news? Leave a comment below and/or share it on your social media. This way, we can inform more people about the hottest things in technology, science, innovation, and gaming!
This news was originally published in:
Original source
